Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.

Nelson, Michael E et al.·Clinical toxicology (Philadelphia·2012·
RPEP-020222012RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.
Published In:
Clinical toxicology (Philadelphia, Pa.), 50(10), 1169-73 (2012)
Database ID:
RPEP-02022

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-02022·https://rethinkpeptides.com/research/RPEP-02022

APA

Nelson, Michael E; Bryant, Sean M; Aks, Steven E. (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.. Clinical toxicology (Philadelphia, Pa.), 50(10), 1169-73. https://doi.org/10.3109/15563650.2012.740637

MLA

Nelson, Michael E, et al. "Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.." Clinical toxicology (Philadelphia, 2012. https://doi.org/10.3109/15563650.2012.740637

RethinkPeptides

RethinkPeptides Research Database. "Melanotan II injection resulting in systemic toxicity and rh..." RPEP-02022. Retrieved from https://rethinkpeptides.com/research/nelson-2012-melanotan-ii-injection-resulting

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.